 "An employee works at the reception area of Cipla at its headquarters in Mumbai")
In an environment which has been challenging, Cipla’s performance in the quarter ended September (Q2) was decent.
Despite challenges on goods and service tax (GST)-led inventory adjustments in the domestic business, India sales grew 12 per cent over a year and 30 per cent sequentially. On a like-to-like basis, adjusted for the impact of GST, domestic sales (40 per cent of overall) grew 19 per cent over a year. Key therapeutic areas such as cardiology, urology, neurology and respiratory, grew ahead of market’s and momentum gain in the diabetes franchisee provides confidence on growth.
Africa, second largest market for Cipla
